Melatonin: Adjunctive, non-opioid for chronic musculoskeletal pain?

Chronic musculoskeletal pain represents a pervasive and debilitating condition, impacting an estimated 20% of the adult population in Europe. This persistent discomfort, often stemming from conditions like osteoarthritis, fibromyalgia, or chronic low back pain, exacts a heavy toll on individuals and healthcare systems. Existing pharmacological interventions, ranging from non-steroidal anti-inflammatory drugs (NSAIDs) to opioids, frequently carry substantial risks, including gastrointestinal bleeding, cardiovascular events, and the well-documented dangers of addiction and overdose. The clinical community has long sought therapies that can effectively reduce pain without introducing these severe liabilities, particularly for long-term management.

Melatonin, an endogenous neurohormone produced primarily by the pineal gland, plays a central role in regulating sleep-wake cycles. Its secretion increases in the evening, signalling the body's preparation for sleep. Beyond its chronobiotic effects, melatonin also exhibits potent antioxidant, anti-inflammatory, and immunomodulatory properties. These broader biological actions have led investigators to explore its potential in various conditions, including pain management. The hypothesis driving this line of inquiry posits that melatonin's anti-inflammatory and analgesic effects, possibly mediated through its interaction with specific receptors (MT1 and MT2) and its free radical scavenging capabilities, could mitigate chronic pain pathways. This mechanism differs significantly from conventional analgesics, offering a distinct therapeutic angle.

What the trial actually measured

A recent meta-analysis, synthesizing data from multiple randomised controlled trials, examined the efficacy and safety of melatonin in patients with chronic musculoskeletal pain. The patient populations across these trials included individuals diagnosed with fibromyalgia, osteoarthritis, chronic low back pain, and temporomandibular joint disorders. Most studies enrolled adults over 18 years of age, with a mean age ranging from 45 to 68 years, reflecting the typical demographic affected by these chronic conditions. The primary endpoint across the included trials was a reduction in pain intensity, typically measured using a Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS) over a follow-up period ranging from 4 to 24 weeks. Secondary endpoints often included improvements in sleep quality, functional status, and quality of life, alongside an assessment of adverse events.

The pooled analysis revealed that melatonin significantly reduced pain intensity compared with placebo. Patients receiving melatonin reported a mean reduction in pain scores of 2.5 points (95% CI, 1.8-3.2; P<.001) on a 0-10 VAS scale, compared to a mean reduction of 0.8 points (95% CI, 0.4-1.2; P=.003) for those on placebo. This difference translates to a clinically meaningful improvement for many patients, particularly given the often refractory nature of chronic musculoskeletal pain. The effect size, while modest, is comparable to or exceeds that seen with some non-opioid pharmacological interventions currently in use. The number needed to treat (NNT) for a 30% pain reduction was approximately 5, indicating that for every five patients treated with melatonin, one additional patient achieved a clinically relevant pain reduction compared to placebo.

Melatonin's impact extended beyond pain reduction. The analysis also showed improvements in sleep quality, a common comorbidity in chronic pain patients. Participants on melatonin reported a mean improvement of 1.2 points (95% CI, 0.7-1.7; P<.001) on a 0-10 sleep quality scale, whereas placebo recipients showed only a 0.3-point improvement (95% CI, -0.1-0.7; P=.15). This dual benefit, addressing both pain and sleep, is particularly relevant given the bidirectional relationship between these two symptoms; poor sleep often exacerbates pain, and vice versa. The doses of melatonin used in the trials varied, typically ranging from 3 mg to 10 mg taken orally at bedtime. No significant dose-response relationship was definitively established across the included studies, suggesting that even lower doses may confer benefit.

Safety data from the meta-analysis indicated melatonin was generally well-tolerated. The incidence of adverse events was comparable between the melatonin and placebo groups. The most commonly reported side effects were mild and transient, including drowsiness, dizziness, and headache. These events occurred in 12% of melatonin-treated patients (95% CI, 9-15%) compared to 10% of placebo-treated patients (95% CI, 7-13%), with no statistically significant difference (P=.21). No serious adverse events were attributed to melatonin in any of the included trials. This favourable safety profile stands in stark contrast to many conventional pain medications, which often carry a higher burden of severe or dose-limiting side effects, making melatonin an attractive option for long-term use.

The individual trials contributing to this meta-analysis employed various methodologies, including double-blind, placebo-controlled designs, which strengthen the overall evidence. However, heterogeneity existed in patient populations, specific pain conditions studied, and duration of treatment. For example, some trials focused exclusively on fibromyalgia, a condition known for its widespread pain and sleep disturbances, while others included patients with more localised joint pain. This variability, while reflecting real-world clinical diversity, also introduces some complexity in interpreting the generalisability of the findings. The duration of follow-up, ranging from 4 to 24 weeks, means that long-term efficacy and safety beyond six months remain less thoroughly investigated. While the NNT of 5 for a 30% pain reduction is encouraging, it also means that a substantial proportion of patients may not achieve this threshold of improvement. Clinicians must manage patient expectations accordingly.

The mechanism by which melatonin exerts its analgesic effects is likely multifactorial. Beyond its direct anti-inflammatory and antioxidant actions, melatonin may modulate pain perception through its influence on central nervous system pathways. It interacts with opioid receptors, albeit indirectly, and can influence neurotransmitter systems involved in pain processing, such as gamma-aminobutyric acid (GABA) and serotonin. Its role in regulating circadian rhythms also cannot be overlooked; by improving sleep, melatonin may indirectly reduce pain sensitivity and improve coping mechanisms. This complex interplay of effects suggests melatonin is not merely a sedative but a pleiotropic agent with broad physiological impacts relevant to chronic pain states. Further research is needed to fully elucidate these intricate mechanisms and identify specific patient phenotypes most likely to respond to melatonin therapy.

The open-label design of some smaller trials included in the meta-analysis is an obvious caveat. While the larger, double-blind studies provide robust data, the inclusion of less rigorously designed trials could introduce bias. The meta-analysis did attempt to account for this by conducting sensitivity analyses, which generally confirmed the overall findings. Still, the lack of standardisation in melatonin formulations and delivery methods across studies also presents a limitation. Melatonin is available in various forms, including immediate-release and extended-release preparations, which may have different pharmacokinetic profiles and, consequently, different clinical effects. Future research should aim for greater uniformity in these aspects to allow for more direct comparisons and clearer guidance on optimal dosing strategies.

The trial was not powered to detect differences in specific pain etiologies, and that gap matters. While the overall effect on musculoskeletal pain was positive, it is unclear whether melatonin is equally effective for neuropathic pain, inflammatory arthritis, or mechanical back pain. Subgroup analyses, where performed, were often underpowered, preventing definitive conclusions about differential efficacy. This means clinicians currently lack precise guidance on which specific chronic pain populations might benefit most. Future, larger trials should focus on specific pain conditions to provide more granular data. Furthermore, the interaction of melatonin with other pain medications was not a primary focus, leaving questions about its role as an add-on therapy versus a monotherapy in complex pain regimens. The potential for drug-drug interactions, particularly with central nervous system depressants, warrants careful consideration in clinical practice.